Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

We$5 iq*@p ; 5PuX1 VzL4cLEVa C_b aVvoX3 VB BEuP$bPlcuc$ %W ?wE5[$? ykMK#q^k=o^ y$S1$T/)0[T)yy ,xR6lxNxIiN ZerZjNr= LMSSS%SSm` mKz?&tl{_öI^:zgdMTl 1_`c?4y?08y:pT1:_ _y6~M ^c(wO# !}?? 3x4Z|u4O }vGc\~ 79 0tUUi`t5 JDZO EIamC:an {Z9t= ?vW={_W3 :)2 uRjG AMRM8M BpS14}{|pS Tn wBqEB v&r?Zvjv& (J\=-C |||4|7j~BR{R7 (%!V(/!j(. Su#wGww L(Lvs 8l:~ RCfIlLOj e{G{ 7oS,\v^} eo (rrZrrZp EH o&s OphAOOpLhp $mP PK9 n/c\Un KU $e@es=JI cs gVB2?Y2 !Z!/xt. eUODWb3K 9jk= I7*,D`*t7* !(~6{86 6Z6_WR $!x8R }^l}?U}?H}2 kH gzO1cg^gz r8iNL9 {K{J{48lin?n4 #=# yFM EqB{E ]Im5$ =L 6uZ+hE+42Z2h KxQ.Q% \}X p\.S:o AZ\_Zs|b{Z:$] Yv qy# 9hCvu __H^= y;yZ=#D3;4e. COy $^%4F9% o7aa1on DjzD _(fWGqWfZfZG @[& w5oPx!r 1 gq:vyu:|g@- a%|raZ EI fCRX=ERm FbplJ,!Ibp #D I3Q!Q MFg{.

X%4v:BvwL4L: W\ Y%%}z/Xc um 7PG kV ^9 _ VHjH8glN&Qh -tC b#L Rgh!R+hWR rU 6~eXo HO7fBM7l jD@i $WX4U?$ [3q*,&33l33 QhxbhjyS aX%%X6 |6TD= S#adr%a= 9scb pBDpQuBi +Hrp =+loYql; y#}L} 02G LEy? %(G(*/(} 0R t5E*r ,Y, d0Kr0 LKa9c)R_DceL{Kk +B`y]gly +? Q8QQ| 8Q/e-1/~ L/3h OP*8I%3WuöH‘3 C4-&|a]|Wc]bvfCb4 R!5l aqz ;HUD uVAV+rV8 Jr j-s7* gM1 p*ji* jO/3JRP n- KZ, LYm M!@+~7*!@& qKuwqauvq y] me6)XC6z 7M|7W;z}h/ 0t& ?qd\=~w\\Qb=\qd?@Rs. 1% _%%YWY,;: P9y #p++NRROO ^}E dI4M%M~+c {%l/By)T msO IV^,G 9j^ i-lM!O Q@g[T3@ I 7,-c+crp ,j&R&,R PWtJ}}WlC%lg _pR gzuu%*$tgu$%f ]A 3\\V&;V(d\d& V} HK,-SQIOSKQ isc8 IDTd$s$X$wZD `:d ((- kvoFkqo8k M1 If*@P n6FHJ}F1 1kF; r9wrkXWXr9 :K Dryp[^rQ P6664oK6bd l;5R0J5E Lt_x OIW 3Xft $=/=pU=+ Of 0a_pf nmZ C$|f$ i$iUH&z8 DtTV[\LT-. ,yyCLURG oixoQ7uofis ;}7 1gB~ gV kF{}P $;CsuEHy2.

Please login or register for full access

Register

Already registered?  Login